尿激酶静脉溶栓治疗急性心肌梗塞疗效相关因素对比研究

对163例尿激酶静脉溶栓治疗急性心肌梗塞（AMI）临床疗效、安全性从不同分层角度进行比较，结果显示：总再通率65.6％，出血率11.0％，5周内死亡率9．2％，起病距溶栓6h内再通率明显高于6b以后（P＜0．01），且死亡率低。不同年龄组6h以内再通率无显著差异（P＞0．05），≥70岁组6h后再通率低于其他年龄组，有显著性差异（P＜0．01）。轻度出血率及死亡率各年龄组无显著差异（P＞0．05）。女性组与男性组比较再通率低、死亡率高、有显著性差异（P＜0．05）。尿激酶剂量以150万u左右为宜。

Relative factors study on intravenous thrombolytic therapy in acute myocardiac infarction

Analysin on our 163 cases, the reliable degree and clinical curatire effect of urokinase intravenous thrombolytic to cure acute myocardiac infarction is that the total reperfusion rate amounts to 65. 6 percent, bleeding rate 11 .0 parcent death rate (within 5 weeks)9.2 percent. When UK was given within 6 hours after AMI onset, the reperfusion rate is clearly higher than 6 hours later (P < 0.01) and the death rate is lower. When UK was given within 6 hours, there is no clear distinction in reperfusion rate amongy groups of different age (P > 0. 05 ). However, compared with other groups,to the over 70 year old groups, the reperfusion rate is lower when UK was given 6 hours later and the distinction is very clear as well (P < 0.01). As to the bleeding rate of light degree and death rate, there is no clear distinction among all the groups (P > 0.05). The female comparing with the male, its reperfusion the is lower while the death rate is higher and there exiots clear distinction (P < 0. 05). The best of the dosage of urokinase is 1 .5 million units or so.